Trial reportBMC anesthesiology2026
Perioperative dexmedetomidine nasal spray improves postoperative sleep in patients undergoing thoracoscopic lung surgery: a prospective, randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Effects of intranasal dexmedetomidine on postoperative sleep quality: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPostoperative sleep disturbance (PSD) is a prevalent postoperative complication that significantly impacts patients' recovery, particularly after thoracoscopic lung surgery .
methodsThis prospective, single center, randomized controlled trial included 117 adult patients aged 18-65 years who underwent elective thoracoscopic lung surgery. They were randomly divided into three groups: 1.0 µg/kg dexmedetomidine nasal spray (Group D), 2.0 µg/kg dexmedetomidine nasal spray (Group HD), and placebo group (Group P). Dexmedetomidine nasal spray or saline (the same device) was administered to the nasal cavity at 21:00-21:30 on the night before surgery, the night of surgery, and the first day after surgery. The primary outcome of this study was the incidence of postoperative sleep disturbance on postoperative day (POD) 1. PSD was defined as a Numeric Rating Scale (NRS)-sleep score of 6 or higher or an Athens Insomnia Scale score of 6 points or higher.
resultsOn the night of surgery, the incidence of PSD in Groups D and HD was lower than that in Group P (30.8%vs.25.6%vs.69.2%, P < 0.001). The NRS-Sleep score of patients in Groups D and HD were significantly higher than those in Group P(4[3,6]vs.4[3,5]vs.5[4,7]; P < 0.001). Furthermore, the Quality of Recovery-15 scores were significantly higher in the Group HD than in the Group P on POD 1 (100.41 ± 8.73 vs.95.49 ± 6.20; P = 0.013) and POD 3 (112.74 ± 7.77vs.107.56 ± 7.06; P = 0.003).
conclusionPerioperative administration of dexmedetomidine nasal spray can effectively improve sleep quality on the night after surgery and improve the quality of recovery after thoracoscopic lung surgery .
trial registrationChinese Clinical Trial Registry (clinical trial number: ChiCTR2500099569, Date of Registration: March 25,2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.